AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
HC Wainwright maintains Buy rating for Sensus Healthcare with PT down to $8.
ByAinvest
Tuesday, Aug 12, 2025 8:18 am ET1min read
HC Wainwright maintains Buy rating for Sensus Healthcare with PT down to $8.
Sensus Healthcare (SRTS) has seen a significant change in analyst sentiment following its Q2 2025 earnings report. The company reported a net loss of $1 million, or $0.06 per share, missing the forecasted EPS of $0.01 [2]. Revenue for the quarter was $7.3 million, down from $9.2 million in Q2 2024 [2]. Despite these disappointing results, Sensus Healthcare continues to focus on international expansion and product development.One of the leading analysts, HC Wainwright, has maintained a Buy rating for Sensus Healthcare but has reduced its price target (PT) to $8 from $12 [1]. This adjustment reflects the company's recent financial performance and the analyst's outlook for future growth prospects. The reduction in the PT indicates a more cautious stance, but it also suggests that the analyst believes there is still potential for the stock to appreciate.
Sensus Healthcare's stock has seen significant volatility in recent months. Following the earnings report, shares fell by 25.79% to $3.97 in premarket trading [2]. The company's financial health score remains at 3.23, indicating that it is trading at elevated earnings and EBITDA multiples [2]. Despite this, the stock appears undervalued based on InvestingPro’s Fair Value analysis [2].
The overall analyst consensus for Sensus Healthcare remains bullish, with a Strong Buy rating based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings [1]. The average price target for Sensus Healthcare is $7.90, with a high forecast of $12.00 and a low forecast of $3.50 [1]. This consensus reflects the analysts' belief in the company's long-term potential despite the recent setbacks.
Sensus Healthcare's focus on international expansion and product development could drive future growth. The company's strategic initiatives aim to capitalize on new markets and innovative products, which could offset the challenges posed by recent financial results.
References:
[1] https://www.tipranks.com/stocks/srts/forecast
[2] https://www.ainvest.com/news/sensus-healthcare-lake-street-maintains-buy-pt-6-13-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet